SV2006002045A - Derivados radiohalogenados de benzamida y su uso en el diagnostico y la terapia de tumores - ref. p-sv-77.998/cd - Google Patents

Derivados radiohalogenados de benzamida y su uso en el diagnostico y la terapia de tumores - ref. p-sv-77.998/cd

Info

Publication number
SV2006002045A
SV2006002045A SV2005002045A SV2005002045A SV2006002045A SV 2006002045 A SV2006002045 A SV 2006002045A SV 2005002045 A SV2005002045 A SV 2005002045A SV 2005002045 A SV2005002045 A SV 2005002045A SV 2006002045 A SV2006002045 A SV 2006002045A
Authority
SV
El Salvador
Prior art keywords
benzamida
radiohalogenated
derivatives
diagnosis
ref
Prior art date
Application number
SV2005002045A
Other languages
English (en)
Inventor
Matthias Friebe
Peter Muschick
Andreas Huth
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of SV2006002045A publication Critical patent/SV2006002045A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

NUEVOS DERIVADOS RADIOHALOGENADOS DE BENZAMIDA Y SU USO EN EL DIAGNOSTICO Y LA TERAPIA DE TUMORES. LOS DERIVADOS RADIOHALOGENADOS DE BENZAMIDA DE ACUERDO CON LA INVENCION EXHIBEN PROPIEDADES NOVEDOSAS Y ESPECIALMENTE VENTAJOSAS, EN PARTICULAR CON RESPECTO A SU CONCENTRACION EN LOS TUMORES Y AL RETARDO DE LOS MISMOS, A SU CONCENTRACION EN EL HIGADO Y A SU ACUMULACION EN SANGRE. LAS DOSIS DE TERAPIA CON RADIACION EN EL TUMOR EN COMPARACION CON EL TEJIDO SALUDABLE DEL CUERPO QUE SE CONSIGUEN CON LOS COMPUESTOS DE ACUERDO CON LA INVENCION SON VENTAJOSAS
SV2005002045A 2004-03-10 2005-03-10 Derivados radiohalogenados de benzamida y su uso en el diagnostico y la terapia de tumores - ref. p-sv-77.998/cd SV2006002045A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004011720A DE102004011720B4 (de) 2004-03-10 2004-03-10 Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie

Publications (1)

Publication Number Publication Date
SV2006002045A true SV2006002045A (es) 2006-02-15

Family

ID=34895161

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002045A SV2006002045A (es) 2004-03-10 2005-03-10 Derivados radiohalogenados de benzamida y su uso en el diagnostico y la terapia de tumores - ref. p-sv-77.998/cd

Country Status (13)

Country Link
US (2) US20110027179A1 (es)
EP (1) EP1722827A2 (es)
JP (1) JP5209299B2 (es)
AR (1) AR048583A1 (es)
DE (1) DE102004011720B4 (es)
GT (1) GT200500046A (es)
MY (1) MY143393A (es)
PA (1) PA8626001A1 (es)
PE (2) PE20091375A1 (es)
SV (1) SV2006002045A (es)
TW (1) TW200539886A (es)
UY (1) UY28801A1 (es)
WO (1) WO2005089815A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085390A1 (en) 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
AU2009289553A1 (en) * 2008-09-05 2010-03-11 Molecular Insight Pharmaceuticals, Inc. Pharmaceutical composition of a radioiodinated benzamide derivative and methods of making the same
EP2657213A1 (en) 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
BR112021001966A2 (pt) 2018-08-15 2021-04-27 Pharmacyl Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença resultante de inflamação patológica
AU2019322564A1 (en) 2018-08-15 2021-03-25 Pharmacyl Ab A new medical treatment for pathologic inflammation
US11717500B2 (en) 2020-02-03 2023-08-08 Pharmacyl Ab Treatment of spondyloarthritis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2642972B1 (fr) * 1989-02-14 1994-08-05 Inst Nat Sante Rech Med Agents pour le diagnostic et le traitement des melanomes, derives halogenes aromatiques utilisables comme de tels agents et leur preparation
US6517811B2 (en) 1993-05-06 2003-02-11 Research Corporation Technologies, Inc. Compounds for cancer imaging and therapy
US5911970A (en) 1993-05-06 1999-06-15 Research Corporation Technologies, Inc. Methods for cancer imaging and therapy using benzamine compounds
WO1994026314A1 (en) 1993-05-06 1994-11-24 John Christy S Compounds for cancer imaging and therapy
DE19519508C2 (de) * 1995-05-31 1997-05-28 Michael Prof Dr Eisenhut Radiohalogenierte Verbindungen und deren Verwendung zur Diagnose und Behandlung von Tumoren, insbesondere Melanomen
US6028111A (en) * 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
JP3041419B2 (ja) * 1998-10-26 2000-05-15 京都大学長 ドパミンｄ４受容体に結合する放射性ヨウ素標識診断剤
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023485A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
US7427390B2 (en) * 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy

Also Published As

Publication number Publication date
JP5209299B2 (ja) 2013-06-12
TW200539886A (en) 2005-12-16
US20110052492A1 (en) 2011-03-03
US20110027179A1 (en) 2011-02-03
PA8626001A1 (es) 2006-07-03
EP1722827A2 (en) 2006-11-22
UY28801A1 (es) 2005-09-30
MY143393A (en) 2011-05-13
PE20091375A1 (es) 2009-10-18
JP2007527889A (ja) 2007-10-04
WO2005089815A3 (en) 2006-06-15
DE102004011720A1 (de) 2005-09-29
DE102004011720B4 (de) 2008-04-03
AR048583A1 (es) 2006-05-10
GT200500046A (es) 2005-10-31
PE20051148A1 (es) 2006-02-16
WO2005089815A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
SV2006002045A (es) Derivados radiohalogenados de benzamida y su uso en el diagnostico y la terapia de tumores - ref. p-sv-77.998/cd
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
GT200600398A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
ATE527998T1 (de) Illudin-analoga als krebsmittel
EA200700321A1 (ru) Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
CL2004000720A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR
CY1114040T1 (el) Συνδυαστικη θεραπεια του καρκινου περιλαμβανουσα αναστολεις των egfr/her2
CY1113160T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
NI200800020A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.
CY1109764T1 (el) Υποκατεστημενα βενζαζολια και χρηση αυτων ως αναστολεις κινασης raf
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
UY28941A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
CL2008003854A1 (es) Compuestos derivados de 2-bencilpiridazinona, inhibidores, reguladores y/o moduladores de met-quinasa; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de un tumor solido, de la sangre o del sistema inmune; kit farmaceutico que comprende una cantidad de dicho compuesto.
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
CY1110341T1 (el) Παραγωγα κιναζολινης και η χρηση τους στην θεραπευτικη αγωγη θρομβοκυτταραιμιας
CL2020002604A1 (es) Ciertos compuestos de pladienolida y métodos de uso.
UY26988A1 (es) Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos.
CY1109836T1 (el) Διαμινοπαραγωγα βιοτινης και τα συζυγιακα τους με μακροκυκλικους χηλικους παραγοντεσς
DE602006018883D1 (de) Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen